This page gives information about a clinical trial called LACEWING. It will help you learn what you need to know about being in it.
To learn more, click below.
Adults with newly diagnosed acute myeloid leukemia or AML who:
US Residents Only
A study of ASP2215 (gilteritinib) by itself, ASP2215 combined with azacitidine or azacitidine by itself to treat adult patients who have recently been diagnosed with acute myeloid leukemia with a FLT3 gene mutation and who cannot receive standard chemotherapy
Keep in mind that people who are in the study may choose to stop at any time.
Being part of a clinical trial takes time and effort for people in it and their caregivers. Here is important information you should know about the LACEWING clinical trial:
Up to 7
Being part of the LACEWING clinical trial takes time and effort for the person in it and their caregiver. You may:
This medicine is experimental. Because of that, the effectiveness has not been established and not all risks are known before starting the clinical trial. Furthermore, you may experience side effects from the clinical trial treatment. People who are in the study may choose to stop at any time.
Based on your answers, you may be a good fit for this study.
A study doctor at the clinical trial center will determine
if you qualify for the study.
To learn more about being in the study, contact a clinical trial center.
To find the clinical trial center closest to you, enter your location below.
Based on your answers, this study may not be right for you. Please talk to your doctor if you still have questions about the LACEWING study. Or, if you still think you may be a good fit for this clinical trial, search below for a clinical trial center near you. You can contact the doctor who is leading the study and speak with them.